

# LIPIDS

TAG, PL and SL metabolism

*Marek Vecka*

# BIOSYNTHESIS OF TAG

## *TWO BIOSYNTHETIC PATHWAYS IN MAMMALS*

### **liver, adipose tissue**

- use mainly **phosphatidate pathway** (“Kennedy pathway”)

### **intestine**

- **monoacylglycerol pathway**

### **mammary glands**

- use **phosphatidate pathway**

# BIOSYNTHESIS OF TAG

## *I. PHOSPHATIDATE PATHWAY*

### = Kennedy pathway



1. synthesis of *sn*-glycerol-3-phosphate
2. synthesis of phosphatidic acid (PA)
  - PA can be utilized for PL synthesis
3. synthesis of TAG

# BIOSYNTHESIS OF TAG

## I. PHOSPHATIDATE PATHWAY

### 1. Synthesis of *sn*-glycerol-3-phosphate

- from glycerol  
in liver
- from glycolytic product dihydroxyacetonephosphate  
in liver << adipose tissue, muscles
- from pyruvate  
in adipose tissue






liver

# BIOSYNTHESIS OF TAG

## I. PHOSPHATIDATE PATHWAY

### 2. Synthesis of phosphatidic acid

- addition of fatty acyls to the positions *sn*-1 and *sn*-2




# BIOSYNTHESIS OF TAG


## I. PHOSPHATIDATE PATHWAY

### 2. Synthesis of phosphatidic acid


- in the endoplasmic reticulum
- many acyltransferases known use Acyl CoA



*G3P*  
*acyltransferase*



*LPA*  
*acyltransferase*




# BIOSYNTHESIS OF TAG


## I. PHOSPHATIDATE PATHWAY

### 3. Synthesis of TAG

- conversion of PA into TAG




→  
*PA*  
*phosphatase*



- in endoplasmic reticulum

↓  
*DAG*  
*acyltransferase*




# BIOSYNTHESIS OF TAG


## II. MONOACYLGLYCEROL PATHWAY

### Occurrence


- enterocytes utilize 2-MAG taken from intestinal lumen
- formation of 2,3-DAG is also possible



*MAG*  
*acyltransferase*



*DAG*  
*acyltransferase*






# DEGRADATION OF TAG

## *Metabolic fate of intracellular TAG*

### overview

- stored TAG are hydrolyzed into fatty acids + glycerol




# DEGRADATION OF TAG

## *Metabolic fate of intracellular TAG*

### 1. Fatty acids as E source

- conversion into activated FA CoA



tricarboxylic  
cycle

ketogenesis

### 2. Fatty acids as part of lipid biosynthesis

- used for resynthesis of TAG, synthesis of PL (+ VLDL in liver)
- synthesis of sphingolipids (sphinganine + acyl moiety)

### 3. Signalling molecules derived from fatty acids

- oxylipins (eicosanoids/docosanoids) after liberation of FA from PL molecule and consequent metabolization

# DEGRADATION OF TAG

## *FA as source of energy*

### **1. Liberation of FA from storage molecule = TAG**

- called fat mobilization
- enzymatically by **lipases**

### **2. Transport FA into the cytoplasm of target cell**

- FA are released into the circulation (albumin bound NEFA)
- transport through the cell membrane

### **3. FA oxidation to acetyl CoA**

a) activation of FA into acylCoA



b) degradation of FA chain by  $\beta$ - ( $\alpha$ -,  $\omega$ -) oxidation

# DEGRADATION OF TAG

## *FA as source of energy*

### **1. Liberation of FA from storage molecule = TAG**

a) higher energy demand

TAG is the richest source of E (up to 38 kJ/g)

- carbon atoms in highly reduced state
- no H<sub>2</sub>O needed for storage (x glycogen)

- during prandial phase
- long term demand = fasting/starvation
- actual consumption of energy = physical exercise

b) part of stress response


- covers high energy demand + formation of signalling molecules

# DEGRADATION OF TAG

## *FA as source of energy*

### 1. Liberation of FA from storage molecule = TAG

TAG are stored as lipid droplets (adipocytes....)




# DEGRADATION OF TAG

*FA as source of energy*

**1. Liberation of FA from storage molecule = TAG**

3 FA are consequently cleaved from TAG molecule



# DEGRADATION OF TAG

## FA as source of energy

### 1. Liberation of FA from storage molecule = TAG

hormonal control of the process

stress (adrenaline)

starving (glucagon)




cAMP ↑



activation  
of PKA



fed state (insulin)



phosphorylation  
of perilipin-1

phosphorylation  
of HSL



TAG lipase =  
desnutrin ↑

HSL = *hormon*  
*sensitive lipase*

TAG



DAG



2-MAG

1<sup>st</sup> NEFA

2<sup>nd</sup> NEFA


glycerol

3<sup>rd</sup> NEFA

# DEGRADATION OF TAG

## FA as source of energy

1. Liberation of FA from storage molecule = TAG  
hormonal control of the process





# DEGRADATION OF TAG

*FA as source of energy*

## 2. Transport of FA to the target cell

extracellular – the circulation

NEFA are bound to albumin

adipose tissue → blood → skeletal muscles, heart, liver

passing through plasma membrane of target cell

passive diffusion

facilitated diffusion – transporting molecules (FATP, CD36)

intracellular – cytoplasmatic

binding proteins (FABPs)


# DEGRADATION OF TAG

## *FA as source of energy*

### 3. FA oxidation to acetyl CoA

#### a) activation of FA into acylCoA

NEFA are converted into acylCoA



FA are activated in various cell compartments:

- VLCFA in peroxisome membranes
- LCFA in outer mitochondrial membranes/ ER
- MCFA, SCFA in mitochondrial matrix

# DEGRADATION OF TAG

*FA as source of energy*

## 3. FA oxidation to acetyl CoA


b) degradation of FA CoA chain by  $\beta$ - ( $\alpha$ -,  $\omega$ -) oxidation  
see lecture on FA biosynthesis and degradation

# BIOSYNTHESIS OF PHOSPHOLIPIDS

## compartmentalization

### Occurrence

- in all nucleated cells (x not in mature ery)



# BIOSYNTHESIS OF PHOSPHOLIPIDS

## *Phosphatidate biosynthesis*

### **1. Synthesis of PA**

- analogous to TAG biosynthesis  
(G3P → LPA → PA)

### **2. Modification of PA with hydrophilic part**


- further activation needed:
  - a) PC, PE: activated alcohol part
  - b) PI, DPG, PG: activated DAG part

# BIOSYNTHESIS OF PHOSPHOLIPIDS



*activated intermediates*

## Cytidine nucleotides

a) for PE, PC synthesis:



b) for PG, DPG, PI synthesis:




# BIOSYNTHESIS OF PHOSPHOLIPIDS


## a) PE and PC biosynthesis

### activation of bases

- dietary sources or membrane PL
- ethanolamine



### choline




# BIOSYNTHESIS OF PHOSPHOLIPIDS

## a) PE and PC biosynthesis

### Synthesis of DAG

- by hydrolysis of PA






# BIOSYNTHESIS OF PHOSPHOLIPIDS

## a) PE and PC biosynthesis

### Conjugation of activated bases with DAG




# BIOSYNTHESIS OF PHOSPHOLIPIDS

## a) PE and PC biosynthesis

### Alternative PC biosynthetic pathway

- during starvation/low choline in diet
- transfer of three methyl groups (donor: SAdMet)
- in liver





# BIOSYNTHESIS OF PHOSPHOLIPIDS

## *PS biosynthesis*

### Exchange reaction

- reversibly from PE or PC
- in endoplasmic reticulum




# BIOSYNTHESIS OF PHOSPHOLIPIDS



## b) PI, PG and DPG biosynthesis

Activated DAG needed

- rapid turnover




*CDP-DAG*  
synthase



# BIOSYNTHESIS OF PHOSPHOLIPIDS

## b) PI, PG and DPG biosynthesis

### PI biosynthesis




# BIOSYNTHESIS OF PHOSPHOLIPIDS


## b) PI, PG and DPG biosynthesis

### PG and DPG (CL) biosynthesis

- DPG is synthesised only in mitochondrion



# BIOSYNTHESIS OF PHOSPHOLIPIDS




# DEGRADATION OF PHOSPHOLIPIDS

## *phospholipases*

### Site specific cleavage of PL

- for glycerophospholipids:






# DEGRADATION OF PHOSPHOLIPIDS

## *phospholipases*

### Phospholipases A<sub>1</sub> (PLA<sub>1</sub>)


- wide tissue distribution
- physiological functions largely unknown
- some of them are PS, PA specific



# DEGRADATION OF PHOSPHOLIPIDS

## *phospholipases*

### Phospholipases A<sub>2</sub> (PLA<sub>2</sub>)



- wide tissue distribution including pancreatic juice
- liberates PUFA from *sn*-2 position of PL



important part of eicosanoid biosynthesis


- part of defense against bacteria, viruses (attack of membranes)
- can hydrolyze oxidized PUFAs in PL
- **inhibited by glucocorticoids**
- PLA<sub>2</sub> in snake venom – generated lysoPL are effective detergents



erythrocyte lysis

# DEGRADATION OF PHOSPHOLIPIDS

## *phospholipases*



## **Phospholipases C (PLC)**


- wide tissue distribution
- production of second messengers (e.g. PI-4,5PP → DAG + IP<sub>3</sub>)
  - high number of PI specific isozymes
    - divided into classes  $\beta$ ,  $\delta$ ,  $\epsilon$ ,  $\gamma$ ,  $\eta$ ,  $\zeta$
- **activated by hormones**

# DEGRADATION OF PHOSPHOLIPIDS

## *phospholipases*

### Phospholipases D (PLD)

- wide tissue distribution
- physiological functions largely unknown (PA + base)
- need phosphoinositides as a cofactor for activity



# BIOSYNTHESIS OF SPHINGOLIPIDS

## *overview*

### **1. Synthesis of sphinganine**

- from serine and palmitoylCoA

### **2. Acylation**

- forming of amide bond (→ ceramides)

### **3. Addition of hydrophilic moiety**


- various groups ( → various sphingolipid classes)

# BIOSYNTHESIS OF SPHINGOLIPIDS

## *sphinganine biosynthesis*

### Condensation of palmitoyl CoA and serine

- NADPH + H<sup>+</sup> needed




# BIOSYNTHESIS OF SPHINGOLIPIDS

## *ceramide biosynthesis*

### Acyl transfer to sphinganine backbone

- *de novo* or products of sphingolipid catabolism



# BIOSYNTHESIS OF SPHINGOLIPIDS

## *further metabolization of ceramides*

### **Hydrophilic part addition**

1. + phosphocholine → **sphingomyelines**

2. + saccharide moiety

+ UDP-activated saccharide units → **glycosphingolipids**

- monosaccharide → *cerebrosides*


- di-, tri- saccharide → *oligoglycosylceramides*

further modification with CMP-activated  
sialic acids → **gangliosides**



# BIOSYNTHESIS OF SPHINGOLIPIDS

## overview



# DEGRADATION OF SPHINGOLIPIDS

## Hydrolytic degradation

- lysosomal hydrolases with saposins (special coactivators)
- sialic acids + sugars + long-chain bases + fatty acids

deficit in enzymes → accumulation of intermediates


→ **metabolic diseases (lysosomal sphingolipidoses)**

- neurological symptoms
- enlargement of liver

# DEGRADATION OF SPHINGOLIPIDS

## Hydrolytic degradation

- lysosomal hydrolases with saposins (special coactivators)



## Further reading

### **Textbooks, monographs**

*Biochemistry of Lipids, Lipoproteins and Membranes (5<sup>th</sup> Ed)*; Vance DE, Vance JE (Eds.), Elsevier, Amsterdam (The Netherlands) 2008

*Lehninger Principles of Biochemistry (6<sup>th</sup> Ed)*; Nelson DL, Cox MM (Eds.), Susan Winslow, New York (U.S.A.) 2013

*Harper's Illustrated Biochemistry (28<sup>th</sup> Ed)*; Murray RK, Bender DA, Botham KM, Kennely PJ, Rodwell VW, Weil PA (Eds.), McGraw-Hill, New York (U.S.A.) 2009

### **Articles**

Vance JE, Vance DE: Phospholipid biosynthesis in mammalian cells. *Biochem Cell Biol* 2004; **82**: 113-128.

Athenstaedt K, Daum G: The life cycle of neutral lipids: synthesis, storage and degradation. *Cell Mol Life Sci* 2006; **63**: 1355–1369.

Forest C, Tordjman J, Glorian M, Duplus E, Chauvet G, Quette J, Beale EG, Antoine B: Fatty acid recycling in adipocytes: a role for glyceroneogenesis and phosphoenolpyruvate carboxykinase. *Biochem Soc Trans* 2003; **31**: 1125-1129

Prentki M, Madiraju SRM: Glycerolipid Metabolism and Signaling in Health and Disease. *Endo Rev* 2008; 29: 647–676.

Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol* 2008; 9: 139-150.

Kolter T, Sandhoff K: Sphingolipid metabolism diseases. *Bioch Biophys Acta* 2006; 758: 2057–2079.

### **Web sources**

<http://www.cyberlipid.org>

<http://lipidlibrary.aocs.org>

<http://www.lipidmaps.org>

<http://www.chem.qmul.ac.uk/iupac> - IUPAC Nomenclature page

<http://themedicalbiochemistrypage.org> - the Medical Biochemistry Page